A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., . . . Ranson, M. (2010). A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.. Journal of Clinical Oncology, 28(15_suppl), 2599. doi:10.1200/jco.2010.28.15_suppl.2599
Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., . . . Ranson, M. (2010). A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.. Journal of Clinical Oncology, 28(15_suppl), 2599. doi:10.1200/jco.2010.28.15_suppl.2599